Sai Life Sciences Limited has informed the Exchange regarding Appointment of Mr Sivaramakrishnan Chittor as Executive Director of the company w.e.f. Jun 17, 2025.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences informed the exchanges that shareholders approved six items via postal ballot on June 16, 2025. Two ESOP schemes (2008 and Management ESOP 2018) were ratified, covering a combined pool of around 1.4 crore equity shares for employees of the company and its subsidiaries/group companies. Dr. Dinesh V Patel, former CEO of Protagonist Therapeutics with 38 years of pharma and biotech experience, was confirmed as Independent Director for a five-year term running until March 2030. Mr. Sivaramakrishnan Chittor, the existing CFO since 2009, was elevated to Whole-Time Director in addition to his CFO role, also for a five-year term. No changes in auditors, promoters, or board departures were reported.
The ratification of pre-IPO ESOP schemes is a routine compliance step and confirms existing employee incentive plans. Adding a Whole-Time Director title to the sitting CFO brings greater board-level accountability for financial oversight, while onboarding a seasoned pharma R&D leader as Independent Director strengthens governance and scientific expertise. These are administrative and governance updates with no immediate financial or share-price impact.